EV-based Liquid Biopsy Market Size is valued at 102.13 Million in 2024 and is predicted to reach 572.43 Million by the year 2034 at an 19.0% CAGR during the forecast period for 2025-2034.
EVs (Extracellular Vesicles) can be categorized based on their cellular origin or size. EVs derived from the intracellular endosomal system are called "exosomes", and vesicles from the plasma membrane are known as "ectosomes" or "microvesicles". Extracellular vesicles are present in all human biofluids and contain DNA, RNA, and proteins originating from their parent cells.
Several clinical research studies have highlighted extracellular vesicles (EVs) as a promising source of novel tumor biomarkers. Tumor EVs in body fluids such as blood have unique properties of cells of origin, making them ideal biomarker candidates for detecting, evaluating, and monitoring tumor growth in liquid biopsies. However, using EVs as cancer biomarkers in routine diagnosis is still hampered by a lack of standardization, data from large patient cohorts, and methodological challenges. Once these issues have been resolved, EVs alone or in combination with other body fluids have the potential to be useful tools in liquid biopsies.
Rising cancer awareness is driving the growth of the EV-based liquid biopsy industry, as liquid biopsy technology can detect cancer at an early stage, monitor tumors, and evaluate diagnosis. In addition, advanced technology development has increased the demand for non-invasive diagnosis and treatment, which is expected to boost the demand for EV-based liquid biopsy in the upcoming years.
The EV-based Liquid Biopsy Market is segmented into offering, workflow, technology, sample type, and end user. By offering, the market is categorized into kits & assays, instruments, and services. The workflow segment comprises sample preparation, sequencing, and data analysis. Based on technology, the market is bifurcated into isolation technologies and detection technologies. The sample type segment is classified into blood (plasma/serum), urine, saliva, other biofluids (CF- cerebrospinal fluid), cell culture. The end user segment consists of academic & research institutions, clinical laboratories, and pharmaceutical & biotechnology companies.
The Kits and Assays segment held the largest EV-based Liquid Biopsy Market share in 2022. The growth can be due to the rising demand for kits. The liquid biopsy market relies on the distance collection of samples by transporting the diagnostics kits to the patient.
In 2022, the Sequencing segment held the largest share of the EV-based Liquid Biopsy Market. The increasing adoption of sequencing, advancements & high efficiency of the Next Generation Sequencing technology to detect the lower frequency variants of cancer are responsible for market expansion.
Factors such as the increasing need for early disease detection and diagnosis, rising public healthcare awareness, and the demand for quick and real-time diagnostic results are expected to boost the demand for detection technologies and, ultimately, for the EV-based Liquid Biopsy Market.
In 2022, the clinical laboratories segment led the EV-based Liquid Biopsy Market and is expected to continue its trend over the projected period, followed by the Pharmaceutical and Biotechnology Companies segment. This is due to the high prevalence of cancer and rising clinical R&D efforts for improving liquid biopsy techniques.
The largest portion of the EV-based Liquid Biopsy Market was held by North America in 2022. The market in this region is being driven by the increasing demand for non-invasive treatments, surging awareness about the applications of liquid biopsies, and rising research efforts to improve early cancer detection. At the same time, the Asia Pacific regional market is expected to witness the fastest growth during the forecast period. Factors such as the escalating cancer cases, increasing adoption of advanced diagnosis techniques, and the increasing government investments in oncology research and treatment are responsible for the blooming of the EV-based Liquid Biopsy Market in Asia Pacific.
| Report Attribute | Specifications |
| Market Size Value In 2024 | USD 102.13 Million |
| Revenue Forecast In 2034 | USD 572.43 Million |
| Growth Rate CAGR | CAGR of 19.0% from 2025 to 2034 |
| Quantitative Units | Representation of revenue in US$ Million and CAGR from 2025 to 2034 |
| Historic Year | 2021 to 2024 |
| Forecast Year | 2025-2034 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Offering, By Workflow, By Technology, By Sample Type, By End User |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; South Korea; South East Asia |
| Competitive Landscape | Abcam plc, AMS Biotechnology Limited (AMSBIO), Bio-Techne Corporation, Horiba Ltd., Qiagen N.V., Thermo Fisher Scientific, Inc., Lonza Group AG, Malvern Panalytical Ltd, Revvity, Inc. (PerkinElmer, Inc.), Takara Bio Inc., Emerging Companies, Mursla Bio, Nanostics Inc., Mercy BioAnalytics, Inc., Clara Diagnostics, Inc. (Clara Biotech), and others. |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing and Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
EV-based Liquid Biopsy Market By Offering-
EV-based Liquid Biopsy Market By Workflow-
EV-based Liquid Biopsy Market By Technology-
EV-based Liquid Biopsy Market By Sample Type-
EV-based Liquid Biopsy Market By End User-
EV-based Liquid Biopsy Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global EV-based Liquid Biopsy Market Snapshot
Chapter 4. Global EV-based Liquid Biopsy Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis of Metaverse Industry
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. COVID-19 Impact on Metaverse Industry
Chapter 5. Market Segmentation 1: By Offering Estimates & Trend Analysis
5.1. By Offering & Market Share, 2024-2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Offering:
5.2.1. Kits and Assays
5.2.2. Instruments
5.2.3. Services
Chapter 6. Market Segmentation 2: By Workflow Containers Estimates & Trend Analysis
6.1. By Offering & Market Share, 2024-2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Workflow Containers:
6.2.1. Sample Preparation
6.2.2. Sequencing
6.2.3. Data Analysis
Chapter 7. Market Segmentation 3: By Technology Estimates & Trend Analysis
7.1. By Offering & Market Share, 2024-2034
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Technology:
7.2.1. Isolation Technologies
7.2.1.1. Precipitation
7.2.1.2. Ultracentrifugation
7.2.1.3. Chromatography
7.2.2. Analysis Technologies
7.2.2.1. NGS
7.2.2.2. PCR
7.2.2.3. Flow Cytometry
Chapter 8. Market Segmentation 4: By Sample Type Estimates & Trend Analysis
8.1. By Offering & Market Share, 2024-2034
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Sample Type:
8.2.1. Blood (Plasma/Serum)
8.2.2. Urine
8.2.3. Saliva
8.2.4. Other Biofluids (CF - Cerebrospinal fluid)
Chapter 9. Market Segmentation 5: By End User Estimates & Trend Analysis
9.1. By Offering & Market Share, 2024-2034
9.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By End User:
9.2.1. Academic and Research Institutions
9.2.2. Clinical Laboratories
9.2.3. Pharmaceutical and Biotechnology Companies
Chapter 10. EV-based Liquid Biopsy Market Segmentation 6: Regional Estimates & Trend Analysis
10.1. North America
10.1.1. North America EV-based Liquid Biopsy Market revenue (US$ Million) estimates and forecasts By Offering, 2021-2034
10.1.2. North America EV-based Liquid Biopsy Market revenue (US$ Million) estimates and forecasts By Workflow Containers, 2021-2034
10.1.3. North America EV-based Liquid Biopsy Market revenue (US$ Million) estimates and forecasts By End User, 2021-2034
10.1.4. North America EV-based Liquid Biopsy Market revenue (US$ Million) estimates and forecasts By, Technology 2021-2034
10.1.5. North America EV-based Liquid Biopsy Market revenue (US$ Million) estimates and forecasts By, Sample Type 2021-2034
10.1.6. North America EV-based Liquid Biopsy Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
10.1.6.1. U.S.
10.1.6.2. Canada
10.2. Europe
10.2.1. Europe EV-based Liquid Biopsy Market revenue (US$ Million) by By Offering, 2021-2034
10.2.2. Europe EV-based Liquid Biopsy Market revenue (US$ Million) estimates and forecasts By Workflow Containers, 2021-2034
10.2.3. Europe EV-based Liquid Biopsy Market revenue (US$ Million) estimates and forecasts By End User, 2021-2034
10.2.4. Europe EV-based Liquid Biopsy Market revenue (US$ Million) estimates and forecasts By Technology,2021-2034
10.2.5. Europe EV-based Liquid Biopsy Market revenue (US$ Million) estimates and forecasts By Sample Type,2021-2034
10.2.6. Europe EV-based Liquid Biopsy Market revenue (US$ Million) by country, 2021-2034
10.2.6.1. Germany
10.2.6.2. Poland
10.2.6.3. France
10.2.6.4. Italy
10.2.6.5. Spain
10.2.6.6. UK
10.2.6.7. Rest of Europe
10.3. Asia Pacific
10.3.1. Asia Pacific EV-based Liquid Biopsy Market revenue (US$ Million) by Offering, 2021-2034
10.3.2. Asia Pacific EV-based Liquid Biopsy Market revenue (US$ Million) estimates and forecasts By Workflow Containers, 2021-2034
10.3.3. Asia Pacific EV-based Liquid Biopsy Market revenue (US$ Million) estimates and forecasts By End User, 2021-2034
10.3.4. Asia Pacific EV-based Liquid Biopsy Market revenue (US$ Million) estimates and forecasts By Technology, 2021-2034
10.3.5. Asia Pacific EV-based Liquid Biopsy Market revenue (US$ Million) estimates and forecasts By Sample Type, 2021-2034
10.3.6. Asia Pacific EV-based Liquid Biopsy Market revenue (US$ Million) by country, 2021-2034
10.3.6.1. China
10.3.6.2. India
10.3.6.3. Japan
10.3.6.4. Australia
10.3.6.5. Rest of Asia Pacific
10.4. Latin America
10.4.1. Latin America EV-based Liquid Biopsy Market revenue (US$ Million) by By Offering, 2021-2034
10.4.2. Latin America EV-based Liquid Biopsy Market revenue (US$ Million) estimates and forecasts By Workflow Containers, 2021-2034
10.4.3. Latin America EV-based Liquid Biopsy Market revenue (US$ Million) estimates and forecasts By End User, 2021-2034
10.4.4. Latin America EV-based Liquid Biopsy Market revenue (US$ Million) estimates and forecasts By Technology, 2021-2034
10.4.5. Latin America EV-based Liquid Biopsy Market revenue (US$ Million) estimates and forecasts By Sample Type, 2021-2034
10.4.6. Latin America EV-based Liquid Biopsy Market revenue (US$ Million) by country, (US$ Million) 2021-2034
10.4.6.1. Brazil
10.4.6.2. Rest of Latin America
10.5. Middle East & Africa
10.5.1. Middle East & Africa EV-based Liquid Biopsy Market revenue (US$ Million) by By Offering, (US$ Million)
10.5.2. Middle East & Africa EV-based Liquid Biopsy Market revenue (US$ Million) estimates and forecasts By Workflow Containers, 2021-2034
10.5.3. Middle East & Africa EV-based Liquid Biopsy Market revenue (US$ Million) estimates and forecasts By End User, 2021-2034
10.5.4. Middle East & Africa EV-based Liquid Biopsy Market revenue (US$ Million) estimates and forecasts By Technology, 2021-2034
10.5.5. Middle East & Africa EV-based Liquid Biopsy Market revenue (US$ Million) estimates and forecasts By Sample Type, 2021-2034
10.5.6. Middle East & Africa EV-based Liquid Biopsy Market revenue (US$ Million) by country, (US$ Million) 2021-2034
10.5.6.1. South Africa
10.5.6.2. GCC Countries
10.5.6.3. Rest of MEA
Chapter 11. Competitive Landscape
11.1. Major Mergers and Acquisitions/Strategic Alliances
11.2. Company Profiles
11.2.1. Abcam plc
11.2.2. AMS Biotechnology Limited (AMSBIO)
11.2.3. Bio-Techne Corporation
11.2.4. Horiba Ltd.
11.2.5. Qiagen N.V.
11.2.6. Thermo Fisher Scientific, Inc.
11.2.7. Lonza Group AG
11.2.8. Malvern Panalytical Ltd
11.2.9. Revvity, Inc. (PerkinElmer, Inc.
11.2.10. Takara Bio Inc.
11.2.11. Emerging Companies
11.2.12. Mursla Bio
11.2.13. Nanostics Inc.
11.2.14. Mercy BioAnalytics, Inc.
11.2.15. Clara Diagnostics, Inc. (Clara Biotech)
11.2.16. Other Prominent Players
EV-based Liquid Biopsy Market By Offering-
EV-based Liquid Biopsy Market By Workflow-
EV-based Liquid Biopsy Market By Technology-
EV-based Liquid Biopsy Market By Sample Type-
EV-based Liquid Biopsy Market By End User-
EV-based Liquid Biopsy Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-